Skip to main content
. 2011 Sep 8;6(9):e23834. doi: 10.1371/journal.pone.0023834

Figure 3. Fibroblast treatment with Hh pathway modulators modifies BODIPY-cholesterol efflux.

Figure 3

NIH 3T3 fibroblasts were cultured in 24-well plates for BODIPY-cholesterol efflux measurements (A and C) or in 100-mm diameter plates for membrane preparations and immunoblotting (B and D), and treated for 48 h with 10 µM cyclopamine (CPN) (A and B) or 100 nM SAG (C and D). CPN and SAG are antagonists and agonists of the Hh pathway, respectively. The histograms presented in A and C are the mean ± SEM of 3 independent experiments (p = 0.04). The Ptc signals from immunoblots presented in B and D and other independent experiments were quantified using Image J software and untreated cells as control.